Pelthos Therapeutics Inc. (NYSEAMERICAN:PTHS) Receives Average Rating of “Moderate Buy” from Analysts

Pelthos Therapeutics Inc. (NYSEAMERICAN:PTHS) has earned an average rating of “Moderate Buy” from the six research firms that are currently covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average 1-year price target among analysts that have issued a report on the stock in the last year is $55.80.

Separately, Oppenheimer lifted their price target on shares of Pelthos Therapeutics from $62.00 to $66.00 and gave the stock an “outperform” rating in a research note on Friday, May 15th.

Pelthos Therapeutics Stock Performance

NYSEAMERICAN PTHS opened at $26.84 on Tuesday. The business’s 50 day moving average price is $27.09 and its 200-day moving average price is $24.86. Pelthos Therapeutics has a fifty-two week low of $16.50 and a fifty-two week high of $37.50. The company has a market cap of $93.40 million, a P/E ratio of -1.30 and a beta of 3.10. The company has a debt-to-equity ratio of 1.41, a quick ratio of 1.86 and a current ratio of 2.79.

Pelthos Therapeutics (NYSEAMERICAN:PTHS) last posted its quarterly earnings data on Thursday, May 14th. The company reported ($3.09) EPS for the quarter. The business had revenue of $10.91 million for the quarter. Sell-side analysts predict that Pelthos Therapeutics will post -12.63 earnings per share for the current year.

Insider Buying and Selling

In other Pelthos Therapeutics news, Director Todd C. Davis acquired 35,948 shares of the business’s stock in a transaction on Thursday, June 11th. The shares were bought at an average price of $27.82 per share, with a total value of $1,000,073.36. Following the transaction, the director directly owned 75,834 shares of the company’s stock, valued at $2,109,701.88. The trade was a 90.13% increase in their position. The purchase was disclosed in a document filed with the SEC, which is available at this link. Over the last 90 days, insiders sold 1,638 shares of company stock valued at $43,107. Corporate insiders own 12.70% of the company’s stock.

Institutional Trading of Pelthos Therapeutics

A number of large investors have recently made changes to their positions in the stock. Persistent Asset Partners Ltd boosted its stake in shares of Pelthos Therapeutics by 150.0% during the fourth quarter. Persistent Asset Partners Ltd now owns 6,007 shares of the company’s stock valued at $186,000 after purchasing an additional 3,604 shares during the period. Pale Fire Capital SE increased its stake in Pelthos Therapeutics by 59.5% in the 1st quarter. Pale Fire Capital SE now owns 12,919 shares of the company’s stock worth $271,000 after buying an additional 4,819 shares during the period. Millennium Management LLC purchased a new position in Pelthos Therapeutics in the 4th quarter worth about $343,000. Geode Capital Management LLC lifted its holdings in Pelthos Therapeutics by 31.9% during the 4th quarter. Geode Capital Management LLC now owns 13,625 shares of the company’s stock valued at $422,000 after buying an additional 3,295 shares in the last quarter. Finally, Knott David M Jr boosted its position in Pelthos Therapeutics by 9.3% in the 1st quarter. Knott David M Jr now owns 21,073 shares of the company’s stock valued at $443,000 after buying an additional 1,792 shares during the period. 77.96% of the stock is owned by hedge funds and other institutional investors.

Pelthos Therapeutics Company Profile

We are a clinical-stage biotech company focused on developing and commercializing new therapeutics to alleviate pain. Our clinical focus is to selectively target the sodium ion-channel known as “NaV1.7”, as well as other receptors in the NaV family. NaV1.7 has been genetically validated as a pain receptor in human physiology. Genetic studies have shown that families with a certain inherited NaV1.7 modulation consistently show a pathology of not feeling pain. A NaV1.7 blocker is a chemical entity that modulates the structure of the sodium-channel in a way to prevent the transmission of pain perception to the central nervous system (“CNS”).